More Noxopharm Ltd. news
Noxopharm Ltd.ASX: NOX

NOXCOVID Trial Advances to Final Stage

Mar 7, 2021 at 10:17 PM EST · Issued by Noxopharm Ltd.

Filed with ASX · Mar 7, 2021 at 10:17 PM EST

On 6ix: 6ix.com/news/noxcovid-trial-advances-to-final-stage

Noxopharm Ltd has released a press release.

View Attachment

6ix hasn’t read this filing yet.

Noxopharm Ltd. on 6ix

Story so far

  • ASCO 2020 Highlights NOX66 Potential in Late-Stage CancerJun 1, 2020
  • Positive DARRT-1 Data in Late-Stage Prostate CancerDec 2, 2019

Earlier from Noxopharm

  • Noxopharm Receives A$4.59M Federal Gov R&D Tax RebateMar 1, 2021
  • Company Announcement Regarding Appendix 3Y DisclosuresFeb 23, 2021
  • Appendix 4D and Half Year Financial ReportFeb 15, 2021
  • LuPIN Survival Outcome Confirmed by Conference PresentationFeb 14, 2021
  • Major Survival Benefit in Prostate Cancer Patients AnnouncedFeb 8, 2021

Later from Noxopharm

  • Noxopharm IONIC Immuno-Oncology Trial CommencesMar 18, 2021
  • Veyonda Patent Lodged for Major Septic Shock OpportunityApr 5, 2021
  • Noxopharm Files Septic Shock Treatment Patent for Veyonda®Apr 14, 2021
  • Veyonda Showing Potential to Prevent Cytokine StormApr 22, 2021
  • March Quarterly Activities Report and Appendix 4CApr 26, 2021
All Noxopharm news releases↗

Follow Noxopharm into a list and get an email when it puts out news.

Follow Noxopharm
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer